Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00422058
Status:
COMPLETED
Last Update Posted:
2017-11-01
First Post:
2007-01-12
Brief Title:
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes A 20-week Randomised Double-blind Placebo-controlled Six Armed Parallel Group Multi-centre Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in Europe The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide
Trial has the following trial periods A 20-week randomised double-blind placebo-controlled six-armed parallel-group multi-centre multinational trial with an open label orlistat comparator arm followed by an 84 week extension period
Trial has the following trial periods A 20-week randomised double-blind placebo-controlled six-armed parallel-group multi-centre multinational trial with an open label orlistat comparator arm followed by an 84 week extension period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-004481-13 | EUDRACT_NUMBER | None | None |